Symptomatic treatment and management of Huntington's disease: An overview

Global Journal of Pharmacology

Volumn 4, Issue 1, 2010, Pages 6-12

  Tyagi, S N ^a   Tyagi, Lalit K ^b   Shekhar, Ravi ^c   Singh, Mahendra ^d   Kori, M L ^e  

^a KNGD Modi Institute of Pharmaceutical Education and Research   (India)

^b Geetanjali College of Pharmaceutical Studies   (India)

^c DR B R AMBEDKAR UNIVERSITY   (India)

^d VELS INSTITUTE OF SCIENCE   (India)

^e Vedica College of Pharmacy   (India)

Author keywords

Bradykynesia; Chorea; Dystonia; Huntington's; Management

Indexed keywords

ALPHA TOCOPHEROL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; BACLOFEN; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; HALOPERIDOL; IDEBENONE; IMIPRAMINE; MINOCYCLINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; QUETIAPINE; RESERPINE; RISPERIDONE; SERTRALINE; SULPIRIDE; TETRABENAZINE; TRANQUILIZER; UNINDEXED DRUG; VALPROIC ACID;

CHOREA; COGNITIVE DEFECT; DEPRESSION; DIET THERAPY; DNA DETERMINATION; DRUG DOSE INCREASE; DRUG MECHANISM; ELECTROCONVULSIVE THERAPY; EMOTIONAL DISORDER; FAMILY THERAPY; GENETIC SCREENING; HUMAN; HUNTINGTON CHOREA; LOW DRUG DOSE; MENTAL DISEASE; MENTAL HEALTH CARE; MUSCLE RIGIDITY; MYOCLONUS; NEUROPSYCHOLOGICAL TEST; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PHYSIOTHERAPY; PRENATAL DIAGNOSIS; PSYCHOSIS; REVIEW; SEIZURE; SOCIAL SUPPORT; SYMPTOMATOLOGY;

EID: 77957859207     PISSN: 19920075     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Martin, R.J. and B.R. Stanley, 1995. Principles of Pharmacology: Basic Concepts and Clinical Applications. Chapman and Hall: New York, USA, pp: 325: 350.
2. Huntington's Disease Association. http://www.hda.org.uk.
3. Rang, H.P., M.M. Dale, J.M. Ritter and P.K. Moore, 2003. Neurodegenerative Disorders. In: Pharmacology. Churchill Living Stone, London, UK. pp: 501.
4. Michael, A.J., 2004. Management of Parkinsonism and Other Movement Disorders. In Basic and Clinical Pharmacology, Eds. Katzung, B.G., Mc Graw Hill Publication, Singapore, pp: 457-458.
5. Harper, P.S., 1992. The Epidemiology of Huntington's Disease. Hum Genet, 89: 365-376.
6. Reiner, A., R.L. Albin, K.D. Anderson et al. 1988. Differential Loss of Striatal Projection Neurons in Huntington's Disease. Proc. Natl. Acad. Sci., 78: 233-238.
7. Albin, R.L., A.B. Young and J.B. Penney, 1989. The Functional Anatomy of Basal Ganglia Disorders. Trends Neurosci., 12: 366-375.
8. Ferrante, R.J., N.W. Kowall and M.F. Beal, 1987. Morphologic and Histochemical Characteristics of a Spared Subset of Striatal Neurons in Huntington's Disease. J. Neuropathol. Exp. Neurol., 46: 12-27.
9. Vonsattel, J.P., R.H. Meyers, T.J. Stevens R.J. Ferrante et al. 1985. Neuropathological Classification of Huntington's Disease. J. Neuropathol. Exp. Neurol., 44: 559-577.
10. Kumar, V., C. Ramsey and R. Stanley, 2003. Robbins Basic Pathology. pp: 844-846.
11. Huntington's Disease Society of America. http://www.hdsa.org.
12. Janchovic, J. and T. Ashizawa, 1995. Huntington's Disease. Current Neurol., 15: 29-60.
13. Haddad, M. and J. Cummings, 1997. Huntington's Disease. Psychiatric Clinics of North America, 20: 791-807.
14. Delong, R.M. and J.L. Jorge, 2005. In: Dennis L. Kasper, Harrison's Principle of Internal Medicine. Mc Graw Hill Publication, pp: 2415.
15. Boon, A.N., R.B. Walker and A.J. Hunter, 2006. Davidson's Principles and Practices of Medicine, pp: 1222-1223.
16. Standaert, G.D. and B.A. Young, 2001. In The Pharmacological Basis of Therapeutics, Eds. J.G. Hardman, L.E. Limbird and A.G. Gilman, McGraw-Hill, Singapore, pp: 562-564.
17. Robert, M.F., 2000. Antibiotic Minocycline May Treat Huntington's Disease. Nature Medicine, 6: 797-801.
18. Shoulson, I., 1992. Huntington's Disease. In Diseases of the Nervous System: Clinical Neurobiology, Eds. W.B. Saunders, Philadelphia, USA, pp: 1159-1168.
19. Pletscher, A., A. Brosi and K.F. Gey, 1962. Benzoquinoline Derivatives: A New Class of Monoamine Decreasing Drugs with Psychiatric Action. Int. Rev. Neurobiol., 4: 275-306.
20. Login, I.S., M.J. Cronin and R.M. Macleod, 1982. Tetrabenazine Has Properties of A Dopamine Receptor Antagonist. Ann. Neurol., 12: 257-262.
21. Dalby, M.A., 1969. Effect of Tetrabenazine in Extra Pyramidal Movement Disorders. Brit. Med. J., 2: 422-423.
22. Shoulson, I., C. Odoroff, D. Oakes, et al. 1989. A Controlled Trial of Baclofen As Protective Therapy in Early Huntington's Disease. Ann. Neurol., 25: 252-259.